PE20121585A1 - ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS - Google Patents
ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOSInfo
- Publication number
- PE20121585A1 PE20121585A1 PE2012000234A PE2012000234A PE20121585A1 PE 20121585 A1 PE20121585 A1 PE 20121585A1 PE 2012000234 A PE2012000234 A PE 2012000234A PE 2012000234 A PE2012000234 A PE 2012000234A PE 20121585 A1 PE20121585 A1 PE 20121585A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- ectodominium
- Prior art date
Links
- 102000056372 ErbB-3 Receptor Human genes 0.000 title 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121585A1 true PE20121585A1 (es) | 2012-11-29 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000234A PE20121585A1 (es) | 2009-08-21 | 2010-08-23 | ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS |
Country Status (21)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| SI3351558T1 (sl) * | 2009-11-13 | 2020-07-31 | Daiichi Sankyo Europe Gmbh | Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 |
| US8859737B2 (en) | 2009-12-22 | 2014-10-14 | Roche Glycart Ag | Anti-HER3 antibodies and uses thereof |
| ES2535503T3 (es) | 2010-03-11 | 2015-05-12 | Merrimack Pharmaceuticals, Inc. | Uso de inhibidores de ErbB3 en el tratamiento del cáncer de mama triple negativo |
| RU2568051C2 (ru) | 2010-04-09 | 2015-11-10 | Авео Фармасьютикалз, Инк. | АНТИТЕЛА К ErbB3 |
| PL2606070T4 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| IT1402149B1 (it) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2. |
| EP3156421B1 (en) * | 2010-11-01 | 2018-06-06 | Symphogen A/S | Pan-her antibody composition |
| EP2699602B1 (en) | 2011-04-19 | 2017-03-01 | Merrimack Pharmaceuticals, Inc. | Bispecific anti-igf-1r and anti-erbb3 antibodies |
| CA2840461A1 (en) * | 2011-06-20 | 2012-12-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbb3 antibody |
| ES2694153T3 (es) | 2011-09-30 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 y usos de los mismos |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CN108753942A (zh) | 2011-10-06 | 2018-11-06 | Aveo制药公司 | 预测肿瘤对抗erbb3抗体的应答 |
| AU2012335543C1 (en) * | 2011-11-09 | 2017-12-14 | Beijing Cotimes Biotech Co., Ltd., | HER3 antibodies and uses thereof |
| UY34487A (es) | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3) |
| HK1201278A1 (en) * | 2012-02-22 | 2015-08-28 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2015058108A1 (en) * | 2013-10-17 | 2015-04-23 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| NZ724013A (en) | 2014-02-28 | 2019-11-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| BR112018008068A2 (pt) | 2015-10-23 | 2018-11-13 | Merus N.V. | moléculas de ligação que inibem o crescimento do câncer |
| EP3600413A1 (en) | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| ES2951864T3 (es) | 2017-05-17 | 2023-10-25 | Merus Nv | Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama |
| US11390686B2 (en) | 2017-08-09 | 2022-07-19 | University Of Saskatchewan | HER3 binding agents and uses thereof |
| FI3665198T3 (fi) | 2017-08-09 | 2025-04-25 | Merus Nv | EGFR:ää ja cMET:tä sitovia vasta-aineita |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| CN116133694A (zh) * | 2020-10-14 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 |
| CA3199259A1 (en) * | 2020-11-20 | 2022-05-27 | Dale L Ludwig | Her3 radioimmunotherapy for the treatment of solid cancers |
| JP2024523885A (ja) * | 2021-06-15 | 2024-07-02 | ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド | 抗ｈｅｒ３抗体、それを含有する抗体薬物複合体及びそれらの用途 |
| CN119013307A (zh) * | 2022-04-13 | 2024-11-22 | 上海翰森生物医药科技有限公司 | 抗体或其抗原结合片段及其医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
-
2010
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/ko not_active Withdrawn
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en active Application Filing
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/pt not_active IP Right Cessation
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/es not_active Application Discontinuation
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/ja not_active Ceased
- 2010-08-23 EA EA201200195A patent/EA201200195A1/ru unknown
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/zh active Pending
- 2010-08-23 MX MX2012002172A patent/MX336091B/es unknown
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/es unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/es unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/es unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/fr unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013506622A (ja) | 2013-02-28 |
| TN2012000057A1 (en) | 2013-09-19 |
| MX336091B (es) | 2016-01-08 |
| SG178509A1 (en) | 2012-04-27 |
| CR20120108A (es) | 2012-06-05 |
| CN103002912A (zh) | 2013-03-27 |
| AU2010284018B2 (en) | 2014-06-05 |
| KR20120059568A (ko) | 2012-06-08 |
| MX2012002172A (es) | 2012-05-29 |
| EA201200195A1 (ru) | 2012-12-28 |
| WO2011022727A3 (en) | 2013-06-27 |
| JP5752687B2 (ja) | 2015-07-22 |
| IL218097A0 (en) | 2012-04-30 |
| IN2012DN01518A (enrdf_load_html_response) | 2015-06-05 |
| AU2010284018A1 (en) | 2012-03-22 |
| AU2010284018C1 (en) | 2015-10-15 |
| CA2771744A1 (en) | 2011-02-24 |
| WO2011022727A2 (en) | 2011-02-24 |
| EP2467164A2 (en) | 2012-06-27 |
| BR112012003809A2 (pt) | 2019-09-24 |
| NI201200027A (es) | 2013-01-29 |
| ECSP12011740A (es) | 2013-02-28 |
| DOP2012000044A (es) | 2012-06-30 |
| ZA201201195B (en) | 2015-07-29 |
| MA33582B1 (fr) | 2012-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121585A1 (es) | ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS | |
| AR087405A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| AR077595A1 (es) | Tratamientos de combinacion | |
| MX2019005617A (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| EP4538372A3 (en) | Anti-trop2 antibody | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| UA106890C2 (uk) | Гуманізоване антитіло до cdcp1 | |
| SG10201906075VA (en) | Methods of treating cancer | |
| BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
| AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| EA032934B1 (ru) | Применение комбинации, содержащей специфически распознающее cd38 антитело и циклофосфамид | |
| NZ592369A (en) | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment | |
| NZ606195A (en) | Methods and compositions for liver cancer therapy | |
| ES2430068T3 (es) | Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina | |
| GB201114051D0 (en) | Compounds and their uses | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| WO2011146568A8 (en) | Predicting response to a her inhibitor | |
| AR070821A1 (es) | Anticuerpo anti- tyrp1 (antitiroxina humana) | |
| MX2016013600A (es) | Método para tratar adenocarcinoma de pulmón. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |